{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:16:33Z","timestamp":1771935393300,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST 111-2636-B-002-019"],"award-info":[{"award-number":["MOST 111-2636-B-002-019"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 112-S0100"],"award-info":[{"award-number":["NTUH 112-S0100"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-02965-4","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T15:01:20Z","timestamp":1711897280000},"page":"537-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome"],"prefix":"10.1007","volume":"57","author":[{"given":"Yee-Jen","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-4859","authenticated-orcid":false,"given":"Chi-Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,31]]},"reference":[{"key":"2965_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, Investigators T-T (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"2965_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"2965_CR3","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","volume":"79","author":"M Writing Committee","year":"2022","unstructured":"Writing Committee M, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr., Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA (2022) 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol 79:e21\u2013e129","journal-title":"J Am Coll Cardiol"},{"key":"2965_CR4","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","volume":"73","author":"N Ferri","year":"2013","unstructured":"Ferri N, Corsini A, Bellosta S (2013) Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 73:1681\u20131709","journal-title":"Drugs"},{"key":"2965_CR5","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ (2014) 2014 AHA\/ACC Guideline for the management of patients with Non-ST-Elevation Acute Coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 64:e139\u2013e228","journal-title":"J Am Coll Cardiol"},{"key":"2965_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK, Smith SC (2016) Jr. 2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol 68:1082\u20131115","journal-title":"J Am Coll Cardiol"},{"key":"2965_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, J\u00fcni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO (2019) 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87\u2013165","journal-title":"Eur Heart J"},{"key":"2965_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, J\u00fcni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367","journal-title":"Eur Heart J"},{"key":"2965_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-009-0737-1","volume":"66","author":"DS Small","year":"2010","unstructured":"Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, Farid NA, Ni L, Jakubowski JA, Salazar DE, Thieu VT, Payne CD (2010) The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy caucasian subjects. Eur J Clin Pharmacol 66:127\u2013135","journal-title":"Eur J Clin Pharmacol"},{"key":"2965_CR10","first-page":"1","volume":"2","author":"O Kwon","year":"2022","unstructured":"Kwon O, Park D-W (2022) Antithrombotic therapy after Acute Coronary syndromes or percutaneous coronary interventions in east Asian populations. JACC: Asia 2:1\u201318","journal-title":"JACC: Asia"},{"key":"2965_CR11","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","volume":"78","author":"S Saito","year":"2014","unstructured":"Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M (2014) Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 78:1684\u20131692","journal-title":"Circ J"},{"key":"2965_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ccd.26279","volume":"88","author":"C Larmore","year":"2016","unstructured":"Larmore C, Effron MB, Molife C, DeKoven M, Zhu Y, Lu J, Karkare S, Lieu HD, Lee WC, Vetrovec GW (2016) Real-world comparison of Prasugrel with Ticagrelor in patients with Acute Coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 88:535\u2013544","journal-title":"Catheter Cardiovasc Interv"},{"key":"2965_CR13","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1136\/heartjnl-2017-312366","volume":"104","author":"I Olier","year":"2018","unstructured":"Olier I, Sirker A, Hildick-Smith DJR, Kinnaird T, Ludman P, de Belder MA, Baumbach A, Byrne J, Rashid M, Curzen N, Mamas MA (2018) British Cardiovascular Intervention S, the National Institute for Cardiovascular Outcomes R. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart 104:1683\u20131690","journal-title":"Heart"},{"key":"2965_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40256-019-00339-3","volume":"19","author":"O De Filippo","year":"2019","unstructured":"De Filippo O, Cortese M, Raposeiras-Roubin FDA, Abu-Assi S, Kinnaird E, Ariza-Sole T, Manzano-Fernandez A, Templin S, Velicki C, Xanthopoulou L, Cerrato I, Rognoni E, Boccuzzi A, Montefusco G, Montabone A, Taha A, Durante S, Gili A, Magnani S, Autelli G, Grosso M, Blanco A, Garay PF, Quadri A, Varbella G, Queija F, Paz BC, Fernandez RC, Pousa MC, Gallo IM, Morbiducci D, Dominguez-Rodriguez U, Valdes A, Cequier M, Alexopoulos A, Iniguez-Romo D, Rinaldi A (2019) Real-World Data of Prasugrel vs. Ticagrelor in Acute myocardial infarction: results from the RENAMI Registry. Am J Cardiovasc Drugs 19:381\u2013391","journal-title":"Am J Cardiovasc Drugs"},{"key":"2965_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcin.2016.02.013","volume":"9","author":"AM Rafique","year":"2016","unstructured":"Rafique AM, Nayyar P, Wang TY, Mehran R, Baber U, Berger PB, Tobis J, Currier J, Dave RH, Henry TD (2016) Optimal P2Y12 inhibitor in patients with ST-Segment Elevation myocardial infarction undergoing primary percutaneous coronary intervention: a Network Meta-Analysis. JACC Cardiovasc Interv 9:1036\u20131046","journal-title":"JACC Cardiovasc Interv"},{"key":"2965_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/phar.2311","volume":"39","author":"GK Dawwas","year":"2019","unstructured":"Dawwas GK, Dietrich E, Winchester DE, Winterstein AG, Segal R, Park H (2019) Comparative effectiveness and safety of Ticagrelor versus Prasugrel in patients with Acute Coronary Syndrome: a retrospective cohort analysis. Pharmacotherapy 39:912\u2013920","journal-title":"Pharmacotherapy"},{"key":"2965_CR17","doi-asserted-by":"publisher","first-page":"e012078","DOI":"10.1161\/JAHA.119.012078","volume":"8","author":"JE Yun","year":"2019","unstructured":"Yun JE, Kim YJ, Park JJ, Kim S, Park K, Cho MS, Nam GB, Park DW (2019) Safety and Effectiveness of Contemporary P2Y(12) inhibitors in an east Asian Population with Acute Coronary Syndrome: a Nationwide Population-based Cohort Study. J Am Heart Assoc 8:e012078","journal-title":"J Am Heart Assoc"},{"key":"2965_CR18","doi-asserted-by":"crossref","unstructured":"Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van\u2019t Hof JR, Rajpurohit A, Farley JF (2022) Comparative effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for secondary Prophylaxis in Acute Coronary Syndrome: a propensity score-matched cohort study. Clin Pharmacol Ther","DOI":"10.1002\/cpt.2797"},{"key":"2965_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Schupke","year":"2019","unstructured":"Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A (2019) Investigators I-RT. Ticagrelor or Prasugrel in patients with Acute Coronary syndromes. N Engl J Med 381:1524\u20131534","journal-title":"N Engl J Med"},{"key":"2965_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/cpt.2806","volume":"113","author":"A Kumar","year":"2023","unstructured":"Kumar A, Lutsey PL, St Peter WL, Schommer JC, Van\u2019t Hof JR, Rajpurohit A, Farley JF (2023) Comparative risk of hospitalized bleeding of P2Y12 inhibitors for secondary Prophylaxis in Acute Coronary Syndrome after Percutaneous Coronary intervention. Clin Pharmacol Ther 113:412\u2013422","journal-title":"Clin Pharmacol Ther"},{"key":"2965_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamainternmed.2016.2751","volume":"176","author":"M Leibowitz","year":"2016","unstructured":"Leibowitz M, Karpati T, Cohen-Stavi CJ, Feldman BS, Hoshen M, Bitterman H, Suissa S, Balicer RD (2016) Association between Achieved Low-Density Lipoprotein Levels and major adverse cardiac events in patients with stable ischemic heart Disease taking statin treatment. JAMA Intern Med 176:1105\u20131113","journal-title":"JAMA Intern Med"},{"key":"2965_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13:273\u2013277","journal-title":"Value Health"},{"key":"2965_CR23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/pds.3574","volume":"23","author":"MS Ali","year":"2014","unstructured":"Ali MS, Groenwold RH, Pestman WR, Belitser SV, Roes KC, Hoes AW, de Boer A, Klungel OH (2014) Propensity score balance measures in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf 23:802\u2013811","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2965_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.jacc.2012.08.964","volume":"60","author":"D Erlinge","year":"2012","unstructured":"Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, Zhou C, Luo J, Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ (2012) Reduction in platelet reactivity with prasugrel 5\u00a0mg in low-body-weight patients is noninferior to prasugrel 10\u00a0mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 60:2032\u20132040","journal-title":"J Am Coll Cardiol"},{"key":"2965_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","volume":"62","author":"D Erlinge","year":"2013","unstructured":"Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, Ten Berg JM, Foley DP, Wagner H, Brown PB, Luo J, Zhou C, Moser BA, Jakubowski JA, Small DS, Winters KJ, Angiolillo DJ (2013) Prasugrel 5\u00a0mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10\u00a0mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 62:577\u2013583","journal-title":"J Am Coll Cardiol"},{"key":"2965_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4070\/kcj.2014.44.2.82","volume":"44","author":"HY Jin","year":"2014","unstructured":"Jin HY, Yang TH, Choi KN, Seo JS, Jang JS, Kim DK, Kim DS (2014) Randomized comparison of the platelet inhibitory efficacy between low dose prasugrel and Standard Dose Clopidogrel in patients who underwent percutaneous coronary intervention. Korean Circ J 44:82\u201388","journal-title":"Korean Circ J"},{"key":"2965_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","volume":"396","author":"HS Kim","year":"2020","unstructured":"Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, Koo BK, Rhew JY, Chun KJ, Lim YH, Bong JM, Bae JW, Lee BK, Park KW, investigators H-R-P-A (2020) Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 396:1079\u20131089","journal-title":"Lancet"},{"key":"2965_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA (2009) Ticagrelor versus Clopidogrel in patients with Acute Coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"2965_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.7326\/M20-1806","volume":"173","author":"M Menichelli","year":"2020","unstructured":"Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, W\u00f6hrle J, Bernlochner I, Richardt G, Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Lahu S, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Sch\u00fcpke S, Kastrati A (2020) Age- and weight-adapted dose of Prasugrel Versus Standard Dose of Ticagrelor in patients with Acute Coronary syndromes: results from a Randomized Trial. Ann Intern Med 173:436\u2013444","journal-title":"Ann Intern Med"},{"key":"2965_CR30","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791\u20131800","journal-title":"N Engl J Med"},{"key":"2965_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12872-020-01603-0","volume":"20","author":"M Wen","year":"2020","unstructured":"Wen M, Li Y, Qu X, Zhu Y, Tian L, Shen Z, Yang X, Shi X (2020) Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord 20:430","journal-title":"BMC Cardiovasc Disord"},{"key":"2965_CR32","doi-asserted-by":"publisher","first-page":"905607","DOI":"10.3389\/fcvm.2022.905607","volume":"9","author":"L Dai","year":"2022","unstructured":"Dai L, Xu J, Jiang Y, Chen K (2022) Impact of Prasugrel and Ticagrelor on platelet reactivity in patients with Acute Coronary Syndrome: a Meta-analysis. Front Cardiovasc Med 9:905607","journal-title":"Front Cardiovasc Med"},{"key":"2965_CR33","doi-asserted-by":"publisher","first-page":"1053867","DOI":"10.3389\/fcvm.2022.1053867","volume":"9","author":"MG Kang","year":"2022","unstructured":"Kang MG, Ahn JH, Kim K, Koh JS, Park JR, Hwang SJ, Park Y, Tantry US, Gurbel PA, Hwang JY, Jeong YH (2022) Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in east Asian patients with acute coronary syndrome. Front Cardiovasc Med 9:1053867","journal-title":"Front Cardiovasc Med"},{"key":"2965_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jcin.2023.05.035","volume":"16","author":"SY Lee","year":"2023","unstructured":"Lee SY, Jeong YH, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, Kim JW, Jang Y (2023) P2Y(12) inhibitor Monotherapy Combined with Colchicine following PCI in ACS patients: the MACT Pilot Study. JACC Cardiovasc Interv 16:1845\u20131855","journal-title":"JACC Cardiovasc Interv"},{"key":"2965_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/CRD.0b013e31815685fa","volume":"16","author":"E Saunders","year":"2008","unstructured":"Saunders E, Ofili E (2008) Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations. Cardiol Rev 16:82\u201388","journal-title":"Cardiol Rev"},{"key":"2965_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.amjcard.2011.11.019","volume":"109","author":"RH Mehta","year":"2012","unstructured":"Mehta RH, Parsons L, Peterson ED (2012) Comparison of bleeding and in-hospital mortality in asian-americans versus caucasian-americans with ST-elevation myocardial infarction receiving reperfusion therapy. Am J Cardiol 109:925\u2013931","journal-title":"Am J Cardiol"},{"key":"2965_CR37","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11739-021-02672-5","volume":"16","author":"S Goto","year":"2021","unstructured":"Goto S, Goto S (2021) Safety of antithrombotic therapy in east Asian patients. Intern Emerg Med 16:1443\u20131450","journal-title":"Intern Emerg Med"},{"key":"2965_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2174\/1570161116666180117103238","volume":"16","author":"JS Bae","year":"2018","unstructured":"Bae JS, Ahn JH, Tantry US, Gurbel PA, Jeong YH (2018) Should Antithrombotic Treatment Strategies in East asians Differ from caucasians? Curr Vasc Pharmacol 16:459\u2013476","journal-title":"Curr Vasc Pharmacol"},{"key":"2965_CR39","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1536\/ihj.20-772","volume":"62","author":"X Hu","year":"2021","unstructured":"Hu X, Zhao W, Zhang Q, Hu H, Luo S (2021) Efficacy and safety of aspirin combined with low-dose P2Y12 receptor antagonists in east Asian patients undergoing PCI. Int Heart J 62:742\u2013751","journal-title":"Int Heart J"},{"key":"2965_CR40","doi-asserted-by":"publisher","first-page":"937261","DOI":"10.3389\/fcvm.2022.937261","volume":"9","author":"W Peng","year":"2022","unstructured":"Peng W, Zhang Y, Lin Y (2022) Low-dose and standard-dose ticagrelor compared with clopidogrel in patients with acute coronary syndromes: a cohort study from China. Front Cardiovasc Med 9:937261","journal-title":"Front Cardiovasc Med"},{"key":"2965_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMra1607714","volume":"384","author":"F Rodriguez","year":"2021","unstructured":"Rodriguez F, Harrington RA (2021) Management of Antithrombotic Therapy after Acute Coronary syndromes. N Engl J Med 384:452\u2013460","journal-title":"N Engl J Med"},{"key":"2965_CR42","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, D\u017eav\u00edk V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381:2032\u20132042","journal-title":"N Engl J Med"},{"key":"2965_CR43","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (2018) ACC\/AHA Versus ESC guidelines on Dual Antiplatelet Therapy: JACC Guideline comparison. J Am Coll Cardiol 72:2915\u20132931","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02965-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02965-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02965-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:12:28Z","timestamp":1713445948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02965-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,31]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2965"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02965-4","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,31]]},"assertion":[{"value":"8 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}